GlassScriptPhysician profile
Laurie L Clair
NPI 1790046548
$293,026.03
in general payments reported to CMS, 2019-2025
26 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51K · 2022: $52K · 2023: $67K · 2024: $50K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $156K · Travel and Lodging: $16K · Food and Beverage: $12K · Consulting Fee: $6,151 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $155,745.00 |
| Travel and Lodging | $16,155.26 |
| Food and Beverage | $12,245.03 |
| Consulting Fee | $6,151.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $217,359.95 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $43,698.33 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $14,172.36 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,597.89 | 2021-2025 | Caplyta |
| Allergan, INC. | $5,225.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $1,582.71 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $758.52 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $692.80 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $642.99 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $551.68 | 2023-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $525.99 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $324.96 | 2022-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $153.18 | 2024 | |
| Novo Nordisk INC | $116.87 | 2022-2024 | Wegovy |
| Neurocrine Biosciences, INC. | $109.52 | 2024-2025 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $94.32 | 2025 | Qelbree |
| Almatica Pharma LLC | $87.62 | 2022-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $84.74 | 2022-2024 | Trintellix |
| Corium, LLC | $68.18 | 2023-2024 | Azstarys |
| Neos Therapeutics, LP | $39.26 | 2024-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $38.68 | 2023-2024 | Quviviq |
| Itamar Medical INC | $24.78 | 2024-2025 | Watchpatone |
| Lilly USA, LLC | $24.76 | 2025 | Zepbound |
| Celgene Corporation | $18.41 | 2024 | |
| Tris Pharma INC | $17.89 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.